Although numerous experimental studies, primarily in animal models, have demonstrated the beneficial effects of GLP-1 agonists (e.g., liraglutide and exenatide) in sepsis, including reduced inflammation, improved organ function, and prolonged survival, their clinical use in humans is not yet routine and remains under investigation. Here, GLP1R is linked to Sepsis.